Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The target population of this interventional study was ACS patients with drug-coated
balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet
therapy compared with dual antiplatelet therapy alone, late lumen loss at 6 months. 2. To
determine the safety of the regimen with bleeding events as the end point. Subjects were
randomly assigned to two groups, one receiving routine DAPT for six months and one receiving
DAPT plus one month of rivaroxaban 2.5 mg bid